Applying PCSK9 Inhibitors to Optimize Outcomes in Patients With Dyslipidemia

Date: Monday, Nov. 13
Time: 6:30-9:30 p.m.
Sponsored by: AcademicCME and the Elsevier Office of Continuing Medical Education
Supported by: Amgen Inc.
Location: Hilton Anaheim, California Ballroom D
Address: 777 W. Convention Way

Please join Dr. Christopher P. Cannon, Dr. Christie M. Ballantyne, Dr. Alan S. Brown, Dr. Robert H. Eckel, Dr. Robert P. Giugliano and Dr. James A. Underberg on Monday, Nov. 13, at the Hilton Anaheim in Ballroom D for an interactive, live CME symposium highlighting optimal treatment and management strategies for patients with dyslipidemia in the era of PCSK9 inhibitors. A buffet dinner will begin at 6:30 p.m. and the educational activity will begin at 7 p.m. The expert faculty will review recent clinical trial and CVD outcomes data, encompassing lipid lowering therapies for the diabetes subgroup. Dyslipidemia guidelines as well as strategies for achieving LDL-C goal will be outlined, particularly for the high-risk patient. The faculty will utilize an interactive panel format to translate evidence-based medicine to optimal clinical decision-making. This CME program will provide cardiologists with vital information for improving healthcare outcomes in patients with dyslipidemia. Register now at

This content is provided as information only and does not reflect the opinions of the AHA, nor does AHA review or approve the programming. These events are not part of the official AHA Scientific Sessions 2017 as planned by the AHA Committee on Scientific Sessions Programming. These events are part of the unofficial symposia offered concurrently with Scientific Sessions.